Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plinabulin vs. Pegfilgrastim in Reducing the Duration of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)

Next Previous
Trial Profile

Plinabulin vs. Pegfilgrastim in Reducing the Duration of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plinabulin (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Pegfilgrastim
  • Indications Chemotherapy-induced damage; Febrile neutropenia
  • Focus Therapeutic Use
  • Acronyms Protective 2
  • Sponsors BeyondSpring Pharmaceuticals

Most Recent Events

  • 15 Dec 2021 Results presented in a BeyondSpring Pharmaceuticals Media Release.
  • 15 Dec 2021 According to a BeyondSpring Pharmaceuticals media release, data presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
  • 10 Jun 2021 Primary endpoint has been met. (Duration of Severe Neutropenia (DSN)), according to a BeyondSpring Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top